The share price of Atara Biotherapeutics Inc. began a slow climb up after the company experienced a steep drop earlier this month. The Thousand Oaks drug ...
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ: ...
Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is ...
After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline ...
Atara Biotherapeutics said on Tuesday the U.S. health regulator had placed a clinical hold on its trials for cancer cell ...
Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report)‘s stock had its “neutral” rating reiterated by analysts at HC ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Iovance Biotherapeutics (IOVA – Research Report) and ...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...
HC Wainwright issued their FY2024 EPS estimates for Atara Biotherapeutics in a research note issued to investors on Wednesday, January 22nd. HC Wainwright analyst R. Burns forecasts that the ...
On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.’s (NASDAQ:ATRA) ...
H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating yesterday.Invest with Confidence: ...
Atara Biotherapeutics, Inc.’s ATRA share price has dipped by 40.50%, which has investors questioning if this is right time to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback